Publications in collaboration with researchers from National and Kapodistrian University of Athens (115)

2025

  1. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 26, Núm. 5, pp. 596-608

  2. Correction to: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development (Blood Cancer Journal, (2025), 15, 1, (15), 10.1038/s41408-025-01212-0)

    Blood Cancer Journal

  3. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

    The New England journal of medicine, Vol. 392, Núm. 18, pp. 1777-1788

  4. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

    Annals of Oncology, Vol. 36, Núm. 4, pp. 361-374

  5. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

    The Lancet Haematology

  6. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    Blood cancer journal, Vol. 15, Núm. 1, pp. 15

2024

  1. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 113, Núm. 5, pp. 593-605

  2. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    New England Journal of Medicine, Vol. 391, Núm. 5, pp. 393-407

  3. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    The New England journal of medicine, Vol. 391, Núm. 5, pp. 408-421

  4. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  5. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  6. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

  7. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

    Haematologica

  8. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial

    European Journal of Haematology, Vol. 113, Núm. 2, pp. 242-252

  9. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  10. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  11. Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 2, pp. e40-e49.e3

2023

  1. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696

  2. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748

  3. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

    Blood, Vol. 141, Núm. 6, pp. 579-591